Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas raised its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 18.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,099 shares of the company’s stock after acquiring an additional 2,067 shares during the quarter. Teacher Retirement System of Texas’ holdings in Protagonist Therapeutics were worth $506,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in Protagonist Therapeutics by 7.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 565,503 shares of the company’s stock valued at $25,448,000 after purchasing an additional 39,850 shares in the last quarter. Cerity Partners LLC boosted its position in Protagonist Therapeutics by 26.7% in the 3rd quarter. Cerity Partners LLC now owns 14,241 shares of the company’s stock valued at $641,000 after buying an additional 3,005 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Protagonist Therapeutics by 1.2% during the third quarter. The Manufacturers Life Insurance Company now owns 115,765 shares of the company’s stock valued at $5,209,000 after acquiring an additional 1,359 shares in the last quarter. FMR LLC increased its position in shares of Protagonist Therapeutics by 4.5% during the third quarter. FMR LLC now owns 454,196 shares of the company’s stock worth $20,439,000 after acquiring an additional 19,737 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of Protagonist Therapeutics by 448.9% in the third quarter. BNP Paribas Financial Markets now owns 20,294 shares of the company’s stock worth $913,000 after acquiring an additional 16,597 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 30,514 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total value of $1,700,850.36. Following the sale, the insider now owns 83,892 shares in the company, valued at approximately $4,676,140.08. This trade represents a 26.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the sale, the director now directly owns 13,130 shares in the company, valued at approximately $712,302.50. This trade represents a 23.35 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,776 shares of company stock worth $3,585,010. 5.40% of the stock is owned by insiders.

Protagonist Therapeutics Stock Down 1.1 %

Shares of NASDAQ PTGX opened at $48.36 on Tuesday. The firm’s 50-day moving average price is $42.77 and its two-hundred day moving average price is $42.89. Protagonist Therapeutics, Inc. has a 52-week low of $24.22 and a 52-week high of $60.60. The stock has a market capitalization of $2.97 billion, a P/E ratio of 18.18 and a beta of 2.34.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $2.07. The business had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. As a group, equities research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PTGX shares. Truist Financial lifted their price objective on Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a report on Tuesday, March 11th. JPMorgan Chase & Co. upped their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $54.00 price objective on shares of Protagonist Therapeutics in a report on Monday, March 10th. The Goldman Sachs Group cut their target price on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating on the stock in a research note on Monday, February 24th. Finally, StockNews.com downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $62.56.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.